Related references
Note: Only part of the references are listed.Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study
Wen-Chang Yu et al.
MEDICINE (2018)
Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
Miaomiao Gou et al.
SCIENTIFIC REPORTS (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
Fang Li et al.
EUROPEAN JOURNAL OF CANCER (2017)
Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ
Wen-Ying Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
Xiuli Feng et al.
ONCOTARGET (2017)
Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
Qiu-Xia Peng et al.
ONCOTARGET (2017)
Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK313/ANG Signaling Pathway in nap Nastc Thyroid Cancer
Zhijian Jin et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
Vivek Asati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M. Tolaney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Cancer therapy and cardiovascular risk: focus on bevacizumab
Panagiota Economopoulou et al.
CANCER MANAGEMENT AND RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
HIF1 alpha and HIF2 alpha: sibling rivalry in hypoxic tumour growth and progression
Brian Keith et al.
NATURE REVIEWS CANCER (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
Yan-jun Mi et al.
CANCER RESEARCH (2010)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy
JR Tonra et al.
CLINICAL CANCER RESEARCH (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Share Paper
